Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Lineage Commitment01:21

Lineage Commitment

3.1K
Commitment is the  process whereby stem cells:
3.1K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of <i>Lippia sidoides</i> Containing-Dentifrice in Children With Dental Caries: A Clinical Study.

International journal of dentistry·2026
Same author

Nile tilapia skin graft as a new treatment for vaginal agenesis in androgen insensitivity syndrome: a case series.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population.

Molecular carcinogenesis·2026
Same author

Analysis of the Matrix Metalloproteinases Family Profile in Gastric Cancer Suggests Key Matrix Metalloproteinases for Tumor Development and Their Clinical Impact.

Molecular carcinogenesis·2026
Same author

WRAP53 is Downregulated in Acute Myeloid Leukemia Patients and Positively Correlates With HTERT Expression.

Cancer reports (Hoboken, N.J.)·2026
Same author

Biosynthesis of Silver Nanoparticles Using Black Pepper (Piper nigrum) Seed Extract and Evaluation of Their Cytotoxicity.

Chemistry & biodiversity·2026

Related Experiment Video

Updated: Sep 5, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.

Igor Valentim Barreto1, Flávia Melo Cunha de Pinho Pessoa1, Caio Bezerra Machado1

  • 1Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Brazil.

Frontiers in Oncology
|July 11, 2022
PubMed
Summary

Leukemic stem cells (LSCs) share similarities with healthy hematopoietic stem cells (HSCs), complicating targeted therapies. Understanding LSC resistance mechanisms is crucial for developing effective treatments and improving patient outcomes.

Keywords:
clinical relapsedrug resistancehematopoietic stem cellsleukemia stem cellmolecular biomarkers

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 5, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Hematopoietic stem cells (HSCs) maintain blood system function in bone marrow (BM).
  • Leukemic stem cells (LSCs) exhibit stemness, including drug resistance and self-renewal, also residing in BM.
  • LSCs are rare, heterogeneous, and share similarities with HSCs, hindering differentiation and targeted therapy.

Purpose of the Study:

  • To review the immunophenotypic characteristics and resistance mechanisms of LSCs.
  • To explore potential therapeutic targets and alternative treatments for LSC-driven malignancies.
  • To highlight the challenges in LSC-specific targeting due to similarities with HSCs.

Main Methods:

  • Review of existing literature on LSC and HSC characteristics.
  • Analysis of LSC heterogeneity, including genetic and metabolic alterations.
  • Discussion of therapeutic strategies and biomarker potential of LSCs.

Main Results:

  • LSCs possess stemness features contributing to drug resistance and disease relapse.
  • LSC heterogeneity presents challenges for identifying universal therapeutic targets.
  • LSC count can serve as a prognostic biomarker and indicator of treatment efficacy.

Conclusions:

  • Targeting LSCs requires identifying markers with high selectivity for LSCs over HSCs.
  • Current therapeutic approaches are limited by the shared characteristics of LSCs and HSCs.
  • Further research into LSC-specific mechanisms is essential for novel treatment development.